eMed

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...

Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO

Safety, Efficacy and Markers Demonstrated in Combination Trial ROCKVILLE, Md., June 06, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics primarily for the treatment of cancer and inflammatorydiseases, announced the presentation of interim data from the Phase1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) incombination w...

Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R)NCD as a Combination Therapy for Glioblastoma Multiforme ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announces the presentation of results of a single-agent Phase 2study for Panzem(...

EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announced the presentation of preclinical results for its Aurorakinase - angiogenesis inhibitor, ENMD-981693. The data werepresented during oral and poster presentations by EntreMedscientists at the 2n...

KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time

Research Breakthrough Will Aid in Developing Therapies to Preventand Reverse Atherosclerotic Heart Disease EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- KineMed, Inc.,a pathway-based drug discovery and development company, announcedtoday the first method for measuring the efflux of cholesterol fromtissues in animals through the pathway known as reverse cholesteroltransport (RCT). RCT i...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

ROCKVILLE, Md., April 19, 2007 /PRNewswire-FirstCall/--EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of preclinical results for MKC-1,its novel cell cycle inhibitor. The data were presented by EntreMedscientists at the American Association for Cancer Research (AACR)Ann...

EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting

Antiproliferative and Antiangiogenic Activity Demonstrated inPreclinical Leukemia and Breast Cancer Models ROCKVILLE, Md., April 17, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of preclinical data for itsclinical-stage product candidate,...

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models

Tumor Inhibition Demonstrated in Lung and Colorectal Cancers ROCKVILLE, Md., April 16, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announced the presentation of results for its preclinical tubulininhibitor compounds. The data were presented by EntreMed scientistsat the A...

EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds

Multiple Mechanisms for Panzem NCD, MKC-1, and ENMD-1198Highlighted at Oncology Drug Discovery Conference ROCKVILLE, Md., March 26, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc., a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of comparative mechanism of actiondata for its three lead clini...